Table 1. Correlation between clinicopathologic feature of patients and intensity of ARF6, NEDD9 and MT1-MMP.

	Clinical Parameters					Cores (%)
Tissues	Grade	Age (y)	Tumor	Cores	Staining	ARF6	NEDD9	MT1-MMP
Normal	NA	37–72	NA	23	Low (1–2)	94.34 ± 0.11	95.45 ± 0.21	97.40 ± 0.21
					High (3–4)	5.66 ± 0.18	4.55 ± 0.11	3.59 ± 0.27
Malignant	Gr .I	36–57	T1. T2	60	Low (1–2)	25.56 ± 0.21	17.45 ± 0.32	20.23 ± 0.21
					High (3–4)	74.44 ± 0.19	82.55 ± 0.19	79.77 ± 0.32
	Gr .II	29–84	T1. T2	120	Low (1–2)	14.98 ± 0.22	10.56 ± 0.24	15.07 ± 0.27
					High (3–4)	85.02 ± 0.15	89.03 ± 0.11	84.93 ± 0.19
	Gr. III	45–80	T1. T2 T3. T4	34	Low (1–2)	10.78 ± 0.12	9.65 ± 0.13	11.30 ± 0.45
					High (3–4)	89.22 ± 0.22	90.44 ± 0.18	88.68 ± 0.36

NOTE: Grade I, indicates well differentiated; Grade II, moderately differentiated; Grade III, poorly differentiated; T1, indicates tumor invades submucosa; T2, tumor invades muscularis propria; T3, tumor invades through muscularis propria into subserosa or into nonperitonealized pericolic or perirectal tissues; T4, tumor directly invades other organs or sturtures and/or perforate. Staining intensity: 0, no staining; 1, weak; 2, moderate; 3, strong. The percentage of cells expressing elevated levels of ARF6, NEDD9 and MT-MMP was high in endometrial tumors compared to normal endometrium. Statistically significant (p < 0.05) values are given in bold.